▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #340 by analyst upside · 2026-06-27
ALLO
Allogene Therapeutics, Inc.
Healthcare · Market Cap $735M · P/E 0x
ANALYST PRICE TARGET
+298.4%
implied upside to consensus target
Current Price $2.13
Consensus Target $8.48
Bull Target $14.0
Bear Target $3.85
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
7
Hold
1
Sell
0
52-Week Low $0.98
52-Week High $4.46
YTD Return +57.8%
FUNDAMENTALS
Market Cap $735M
P/E Ratio (TTM) N/A
Forward P/E -3.1x
EPS (TTM) $-0.77
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) N/A
Profit Margin N/A
52-WEEK RANGE
52-Week Low $0.98
52-Week High $4.46
Current Price $2.13
Bear Target $3.85
Bull Target $14.0
● Now $2.13 ● Target $8.48
TRADING DATA
Avg Volume 10.4M
YTD Return +57.8%
Analyst Count 10
Consensus Buy
Upside to Target +298.4%
Last Updated 2026-06-27

ANALYST SUMMARY

Allogene Therapeutics, Inc. (ALLO) is currently trading at $2.13 with a Wall Street consensus price target of $8.48, implying potential upside of 298.4% over the next 12 months. 10 analysts currently cover ALLO, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $3.85.

ALLO operates in the Healthcare sector with a market capitalisation of $735M. The stock is up 57.8% year-to-date and is currently trading near the lower end of its 52-week range of $0.98 – $4.46.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

OMER +361.4%
Omeros Corporation
$627M · P/E 7.6x · Underperform
ABEO +251.4%
Abeona Therapeutics Inc.
$320M · P/E 5.9x · Buy
NAGE +268.4%
Niagen Bioscience, Inc.
$272M · P/E 16.3x · Buy
PALI +414.0%
Palisade Bio, Inc.
$328M · P/E 15.8x · Buy
PLX +378.3%
Protalix BioTherapeutics, Inc.
$185M · P/E 12.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ALLO, with each firm's 90-day track record across all stocks we track. See full firm rankings →

JP Morgan ↑ Upgrade
Underweight → Neutral 2026-04-16 43% win rate (7 calls)
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-04-16 31% win rate (48 calls)
Jefferies — Reiterated
Buy → Buy 2026-04-15 50% win rate (6 calls)
Bernstein — Reiterated
Market Perform → Market Perform 2026-04-14 Building track record
Argus Research — Reiterated
Market Perform → Market Perform 2026-04-14 Building track record
Citizens — Reiterated
Market Outperform → Market Outperform 2026-04-14 Building track record
Baird — Reiterated
Outperform → Outperform 2026-04-14 Building track record
HC Wainwright & Co. — Reiterated
Buy → Buy 2026-04-14 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →